Premier Power Renewable Energy, Inc. (PPRW): Company Objectives Our goals...

Papa Bear · 2011-09-16T03:31:46.7370000Z

Company Objectives Our goals are simple. As a solar power company, we aim to build solar energy systems that produce enough electricity to reduce or eliminate your dependency on conventional energy. At the same time, our solar power systems contribute to the conservation of energy resources and the increased use of clean solar energy.

Play Episode

4min

Proactive - Interviews for investors

Southern Cross Gold reveals Sunday Creek scale

Southern Cross Gold Consolidated CEO Michael Hudson talked with Proactive at the AIM's Small and Midcap Conference about the company’s focus on gold and antimony exploration in Victoria, Australia, particularly at the Sundae Creek project. Hudson outlined the scale and significance of the discovery, describing it as “one of the most exciting gold discoveries globally… a rare tier one multi-million ounce high grade discovery.” The company is advancing exploration rapidly, with six drill rigs currently operating and plans to expand to eight. Hudson said the company has completed around 70km of drilling and estimates an exploration target of 2.2 to 3.2 million ounces gold equivalent, grading between 8.5 to 10.6 grams per tonne – all within just 5% of the identified trend. Antimony also plays a key role. Hudson explained that China and Russia dominate the global market and recent export bans have highlighted supply vulnerabilities: “You don't have a defense industry without it. And the Western world really doesn't have it. We've got it.” Hudson also reflected on the company’s recent inclusion in the All Ordinaries Index, following the merger of Canadian and Australian entities. He said it marks the first index entry for Southern Cross Gold Consolidated and is “a reflection on a business that's less than three years old.” #SouthernCrossGold #SundayCreek #GoldExploration #Antimony #ASX #MiningStocks #JuniorMiners #ResourceInvesting #MichaelHudson #AllOrdinaries #GoldAndAntimony #AustralianMining

Proactive - Interviews for investors

Airtasker CEO on growth, AI & global expansion

Airtasker Ltd CEO Tim Fung talked with Proactive at AIM's Small and Midcap Conference about the company’s strategic focus across innovation, growth, and international expansion.** Fung outlined how Airtasker differentiates itself in the local services marketplace by operating as a community platform, where both customers and taskers set job scopes and pricing, rather than the company enforcing set rates. He emphasised Airtasker’s approach to worker empowerment, noting, *“The top people on our platform are running 150, 200 thousand dollars a year doing these kinds of jobs.”* Fung also acknowledged the challenges of the current consumer environment, pointing to Airtasker’s 14.8% revenue growth in the half as a result of lean operations and renewed brand investment. A key part of Airtasker’s strategy involves innovation across customer acquisition, user experience, and operational efficiency—highlighting its collaboration with OpenAI and use of AI tools like Copilot and Zendesk AI. Fung also discussed partnerships, including one with Visa Cash App Racing Bulls, as examples of how Airtasker showcases the diverse range of skilled work enabled by the platform. He concluded by outlining the investor case: a cash-generative, proven business model in Australia being used to fund international growth in the US and UK, offering upside potential with limited downside. #Airtasker #TimFung #ASX #GigEconomy #AIIntegration #MarketplacePlatform #SmallCapStocks #TechInnovation #FY25Strategy #ProactiveInvestors #OpenAI #GlobalExpansion #InvestorUpdates #StartupGrowth

Proactive - Interviews for investors

BluGlass talks quantum sensing & commercial wins

BluGlass Head of Corporate and Investor Relations Stefanie Winwood talked with Proactive at the AIM's Small and Midcap Conference about the company’s work in gallium nitride (GaN) laser technology and its growing role in quantum sensing, computing, and defense applications. Winwood explained that gallium nitride is a compound semiconductor that can conduct electrons significantly faster than traditional silicon. BluGlass is one of a few companies globally producing visible lasers using GaN, a technology that is crucial in precision applications such as post-GPS navigation and quantum computing. “BluGlass is leading the market in the precision applications and these precision applications are the ones that are growing more rapidly,” Winwood said. The company works with large clients such as the US Department of Defense and major semiconductor players like General Electric and Coherent. BluGlass has recently secured contracts worth USD 6 million and aims to build long-term, revenue-generating relationships through projects that can lead to multi-decade manufacturing deals. In addition to commercial traction, BluGlass has strengthened its leadership with the appointment of industry veterans, including Nobel Laureate Shuji Nakamura. The company also recently demonstrated a world-record performance combining power and precision for quantum use cases. #BluGlass #QuantumComputing #GaNtechnology #GalliumNitride #Semiconductors #QuantumSensing #DefenseTech #LaserTechnology #InvestorUpdates #TechInnovation

Proactive - Interviews for investors

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning. For more company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Followers	1267
Posts	65758
Boards Moderated	1
Alias Born	07/30/2010

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

PPRW Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free